Anagrelide vs Ibritumomab

Interacting Drugs
Anagrelide
vs
Ibritumomab
Security Level
Minor, Monitor Therapy
Mechanism
Ibritumomab: Antiplatelet Agents may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.
Management
Monitor therapy

Subscribe for latest updates

Subscribe to our e-mail newsletter to receive updates.

No comments yet.

Post Review about Anagrelide vs Ibritumomab


Other Interactions of Anagrelide

We are Developing Our database, More results coming soon.

Other Interactions of Ibritumomab

We are Developing Our database, More results coming soon.